Navigation Links
PaedRegCliNet e.V.: A Boost for Safe Pediatric Medications
Date:11/19/2010

PaedRegCliNet e.V.: A Boost for Safe Pediatric Medications -- MUNICH, November 19, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries, Children-related News Click to view news release full screen  

PaedRegCliNet e.V.: A Boost for Safe Pediatric Medications

 

MUNICH, November 19, 2010 /PRNewswire/ -- Many of the medications used to treat children have been developed almost exclusively for adults and approved for them. This is why pediatricians have been demanding for decades that medications be tailored specifically to the needs of the child's body and adequately tested on children. A regulation from the European Commission called the Pediatric Regulation has set out to solve this problem. Clinical studies involving children should ultimately give way to medications tailored for this age group. The studies include not only testing substances from adult medications especially for children, but also the additional development and testing of entirely new medications for children.

Paving the way for clinical studies with children

But implementing this extremely positive endeavor has run into two major obstacles. "Because there have hardly been any clinical studies with children, many doctors at pediatric clinics do not have the necessary training," says Prof Dieter Adam. And that is why he founded the association PaedRegCliNet e.V. together with other pediatric specialists. It offers doctors at pediatric clinics one to two-day courses, which provide them with the basis for clinical studies in pediatrics, from the necessary infrastructure to the monitoring and implementation at testing centers. These courses were presented in detail at a symposium held at the Dr. Haunerschen Kinderspital of the University of Munich on September 29, 2010.

Ethical obligation overrides profit

The second problem encountered in implementing the Pediatric Regulation is finding a pharmaceutical company to finance the study. An EU proposal does contain a mention of assuming up to 50 percent of the costs of research on particular medications. "But for companies this does not appear to be attractive," explains Prof Adam.

"Compared to adults, children are not a revenue driver." He explained this fact by using the example of high blood pressure. A medication for high blood pressure approved for adults will be prescribed to millions of patients. If the medication is to be tested to see if it is safe for babies who suffer from high blood pressure due to a congenital heart disease, there are only a few thousand young patients worldwide who would be prescribed this medication. This is why PaedRegCliNet e.V. is also committed to finding pharmaceutical companies, raising awareness of the EU regulation and to underscoring the ethical obligation.

Lowering the costs of the studies

In an effort to keep the costs of the studies as low as possible and to consequently burden pharmaceutical companies as little as possible, the specialists are striving to shorten the studies or to perform them with as few young patients as possible. To do this, they are using archived patient data in pediatric clinics on the so-called "off-label application" of adult medications. If there is no other way to save the health of the child, the doctors have to use these medications even without specific approval for children. "We plan to view and anonymously assess the files in question," states Prof Adam about the project. Some medications often prove to be effective and safe for many thousands of young patients. If one then considers these facts in a clinical study, it can be carried out with significantly less effort. Unfortunately, government organizations have not yet agreed to offer financial support to this project.

The non-profit organization PaedRegCliNet e.V. was founded in 2009 and is committed to promoting the development of medications for children and to supporting this through its own projects. As a member, you help ensure that children across Europe are given adequately tested medications.

More Information: PaedRegCliNet e.V. Jurgen Wyen Tel.: +49-89-55155358 Fax: +49-89-55155359 Juerge.Wyen@PaediaCRO.de
'/>"/>

SOURCE PaedRegCliNet. e.V.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prolong Pharmaceuticals Boosts Executive Team
2. ALS Research Gets a $4.1 Million Boost from CVS/pharmacy Fundraising Campaign
3. Electronic Recordkeeping Boosts Patient Safety, Saves DMC More Than $5 Million - For Second Straight Year
4. George Soros to Boost Civil Society Response in Flood Affected Areas of Pakistan
5. Study Seeks Volunteers to Measure Safety of Treatment Boost for Patients with Oropharyngeal Cancer
6. Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity
7. MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimers Disease Trials
8. Verizon Business Adds Riverbed Application Acceleration Technology, New Consulting Services to Boost Performance of Key Business Applications
9. First Coast Oncology Deploying Both Naviscan(TM) PEM and AccuBoost(TM) Assisted Therapy to Optimize Breast Cancer Treatment
10. $500 Billion Health Care Spend Boosts BRIC Countries Diagnostic Imaging Sales Despite Global Recession, According to Millennium Research Group
11. Widening Application Range to Boost MRI Markets in Eastern Europe, Says Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
(Date:4/27/2016)... April 27, 2016 At the ... launch of a Phase 2 clinical study of its ... patients undergoing cochlear implantation (CI) surgery. This large, placebo-controlled, ... Germany and France ... ear at the time of surgery. "Despite advances in ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick Wilson ... Rio. Under the care of Maximized Living doctors at the London Olympics in ... Maximized Living is sending the largest contingent of elite chiropractors to Rio to support ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... by the Accreditation Council for Graduate Medical Education (ACGME) that it has received ... is the first accreditation of three residency programs that Memorial is currently pursuing, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... . Dr. Bernie Siegel, author of a plethora of essential books-to-read for ...
(Date:4/29/2016)... Southlake, Texas (PRWEB) , ... April 29, 2016 , ... ... and neck pain, is proud to announce one of their physicians has been invited ... Osteopathic Family Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Melanoma is the deadliest type of skin cancer. ... for the majority of skin cancer deaths. More than 10,000 people are expected to die ... diagnosis is 62, it is the one of the most commonly diagnosed cancers in young ...
Breaking Medicine News(10 mins):